Edaravone is a neuroprotective agent, and several studies have suggested that it may be beneficial in acute ischaemic stroke.
Objectives. To assess the efficacy and safety of edaravone for acute ischaemic stroke.
Main results. Authors included three trials. All three included trials were of edaravone plus another treatment compared with the other treatment alone. The dose of edaravone injections in the three trials was the same at 60 mg per day. The course of treatment in all three trials is 14 days. All three trials reported adverse events; there were no differences between the treatment group and the control group. Overall, edaravone appeared to increase the proportion of participants with marked neurological improvement compared with the control group, and the difference was significant (risk ratio (RR) 1.99, 95% confidence interval (CI) 1.60 to 2.49).